Amsterdam UMC
Verified site
Amsterdam, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
People with Pulmonary Hypertension Associated with Interstitial Lung Disease have high blood pressure in the tiny vessels of the lungs caused by scarring of lung tissue, which can make breathing and exercise difficult. The study is testing an inhaled medication called mosliciguat, which is delivered as a dry powder that participants breathe in, and comparing it with a harmless inhaled placebo that looks the same but contains no active drug.
The purpose of the study is to evaluate the effect of mosliciguat compared to placebo on exercise capacity. Participants will be randomly assigned to receive either the study drug or the placebo, will use the inhaled powder twice daily, and will be followed for several months while continuing their usual care.
During the trial, participants will perform a simple walking test called the 6-Minute Walk Distance, which measures how far they can walk in six minutes, to see if the medication helps them walk farther. They will also have regular check‑ins where doctors ask about symptoms and may do routine tests to monitor safety and overall health.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
6 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Amsterdam, The Netherlands
Leuven, Belgium
Nijmegen, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
MOSLICIGUAT is an inhaled powder being tested in this study. Participants will breathe the medication into their lungs using a special inhaler. The drug is being evaluated to see if it can help improve the ability to exercise in people who have pulmonary hypertension linked to interstitial lung disease. Researchers are watching how safe it is and whether it can make breathing easier and increase activity tolerance.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.